Acneiform Eruptions Possibly Triggered by Clarithromycin During Sirolimus Treatment.

acneiform eruption clarithromycin cyp3a drug-drug interactions egfr mtor sirolimus

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
May 2024
Historique:
accepted: 25 05 2024
medline: 26 6 2024
pubmed: 26 6 2024
entrez: 26 6 2024
Statut: epublish

Résumé

Acneiform eruption is the recognized dermatological side effect of sirolimus, an inhibitor of the mammalian target of rapamycin, although the pathophysiological mechanisms and dose dependency of this side effect remain unclear. This case report describes a case of a 40-year-old Japanese woman treated with systemic sirolimus who developed acneiform eruptions following the administration of clarithromycin. The acneiform eruption resolved after discontinuation of sirolimus and relapsed with the resumption. Since sirolimus and clarithromycin have a potential drug-drug interaction mediated by cytochrome P450 3A (CYP3A), this case suggests that the acneiform eruption developed in association with elevated blood levels of sirolimus. We conclude that clinicians should be aware of the possibility of developing acneiform eruption during sirolimus treatment, especially when administered with medications that inhibit CYP3A.

Identifiants

pubmed: 38919203
doi: 10.7759/cureus.61084
pmc: PMC11196916
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

e61084

Informations de copyright

Copyright © 2024, Kataoka et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Koki Kataoka (K)

Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JPN.

Saeko Nakajima (S)

Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JPN.
Drug Discovery for Inflammatory Skin Diseases, Kyoto University Graduate School of Medicine, Kyoto, JPN.

Takashi Nomura (T)

Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JPN.
Drug Development for Intractable Diseases, Kyoto University Graduate School of Medicine, Kyoto, JPN.

Kenji Kabashima (K)

Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JPN.
A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, SGP.
Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, SGP.

Classifications MeSH